Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

TY - JOUR

T1 - Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

AU - Ahmad, Zahid

AU - Pordy, Robert

AU - Rader, Daniel J.

AU - Gaudet, Daniel

AU - Ali, Shazia

AU - Gonzaga-Jauregui, Claudia

AU - Ponda, Manish P.

AU - Shumel, Brad

AU - Banerjee, Poulabi

AU - Dunbar, Richard L.

N1 - Funding Information: This study was sponsored by Regeneron Pharmaceuticals, Inc. The sponsor was involved in the study design and collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. The authors had unrestricted access to study data, were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication. Dr Ahmad has received grants from Regeneron Pharmaceuticals Inc during the conduct of the study; has received personal fees from Regeneron Pharmaceuticals Inc, Amgen, and Akcea; and has received grants from the National Institutes of Health-National Heart, Lung, and Blood Institution and FH Foundation outside of the submitted work. Drs Pordy, Ali, Banerjee, Gonzaga-Jauregui, Ponda, and Shumel are employees and shareholders of Regeneron Pharmaceuticals, Inc. Dr Rader has received consultant fees/honoraria for scientific advisory board participation from Alnylam, Novartis, Pfizer, and Verve; and has ownership interest/partnership/principal in Staten Bio and Vascular Strategies. Dr Gaudet has received research grant support from Acasti, Akcea, Aegerion, Amgen, AstraZeneca, Boehringer Ingelheim, Canadian Cardiovascular Research Network, Cerenis, Dalcor Pharma, Esperion, Gemphire, GlaxoSmithKline, HDL Therapeutics, Ionis Pharmaceuticals, Ironwood, Lilly, Kowa, Novartis, Pfizer, Regeneron, Sanofi, and UniQure; and has served as a consultant for Akcea, Aegerion, Amgen, HDL Therapeutics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc, and Sanofi; he has no financial interest in Regeneron Pharmaceuticals Inc. Dr Dunbar has received grants and nonfinancial support from Regeneron Pharmaceuticals Inc during the conduct of the study; has received grants from Ionis, UniQure, Akcea, Amarin, and AstraZeneca outside of the submitted work; was employed by ICON Clinical Services during the bulk of the paper preparation; and is currently an employee and stock shareholder of Amarin Pharma, Inc. The authors wish to dedicate this research letter to the memory of Daniel A. Gipe, MD, who died prematurely and unexpectedly during the course of the evinacumab studies. The authors are all profoundly indebted to him for his significant personal contribution to the recent advancements in the field that are here described, and for his friendship. The authors also thank the participants, their families, and investigators involved in this study. Kuo-Chen Chan, PhD, and Jennifer McGinniss, PhD, from Regeneron Pharmaceuticals, Inc, conducted the statistical analysis for this study. The following people from Regeneron Pharmaceuticals Inc provided editorial comments on the paper: Marc Israel, Pharma D, Eva-Lynne Greene, MSc, and Scott Mellis, MD, PhD. Medical writing assistance under the direction of the authors was provided by Aparna Shetty, PhD, Atif Riaz, PhD, and Rob Campbell, PhD, of Prime (Knutsford, United Kingdom), funded by Regeneron Pharmaceuticals Inc, according to Good Publication Practice guidelines. Funding Information: This study was sponsored by Regeneron Pharmaceuticals, Inc. The sponsor was involved in the study design and collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. The authors had unrestricted access to study data, were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication. Dr Ahmad has received grants from Regeneron Pharmaceuticals Inc during the conduct of the study; has received personal fees from Regeneron Pharmaceuticals Inc, Amgen, and Akcea; and has received grants from the National Institutes of Health-National Heart, Lung, and Blood Institution and FH Foundation outside of the submitted work. Drs Pordy, Ali, Banerjee, Gonzaga-Jauregui, Ponda, and Shumel are employees and shareholders of Regeneron Pharmaceuticals, Inc. Dr Rader has received consultant fees/honoraria for scientific advisory board participation from Alnylam, Novartis, Pfizer, and Verve; and has ownership interest/partnership/principal in Staten Bio and Vascular Strategies. Dr Gaudet has received research grant support from Acasti, Akcea, Aegerion, Amgen, AstraZeneca, Boehringer Ingelheim, Canadian Cardiovascular Research Network, Cerenis, Dalcor Pharma, Esperion, Gemphire, GlaxoSmithKline, HDL Therapeutics, Ionis Pharmaceuticals, Ironwood, Lilly, Kowa, Novartis, Pfizer, Regeneron, Sanofi, and UniQure; and has served as a consultant for Akcea, Aegerion, Amgen, HDL Therapeutics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc, and Sanofi; he has no financial interest in Regeneron Pharmaceuticals Inc. Dr Dunbar has received grants and nonfinancial support from Regeneron Pharmaceuticals Inc during the conduct of the study; has received grants from Ionis, UniQure, Akcea, Amarin, and AstraZeneca outside of the submitted work; was employed by ICON Clinical Services during the bulk of the paper preparation; and is currently an employee and stock shareholder of Amarin Pharma, Inc. The authors wish to dedicate this research letter to the memory of Daniel A. Gipe, MD, who died prematurely and unexpectedly during the course of the evinacumab studies. The authors are all profoundly indebted to him for his significant personal contribution to the recent advancements in the field that are here described, and for his friendship. The authors also thank the participants, their families, and investigators involved in this study. Kuo-Chen Chan, PhD, and Jennifer McGinniss, PhD, from Regeneron Pharmaceuticals, Inc, conducted the statistical analysis for this study. The following people from Regeneron Pharmaceuticals Inc provided editorial comments on the paper: Marc Israel, Pharma D, Eva-Lynne Greene, MSc, and Scott Mellis, MD, PhD. Medical writing assistance under the direction of the authors was provided by Aparna Shetty, PhD, Atif Riaz, PhD, and Rob Campbell, PhD, of Prime (Knutsford, United Kingdom), funded by Regeneron Pharmaceuticals Inc, according to Good Publication Practice guidelines.

PY - 2021/7/13

Y1 - 2021/7/13

UR - http://www.scopus.com/inward/record.url?scp=85108648242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108648242&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2021.04.091

DO - 10.1016/j.jacc.2021.04.091

M3 - Letter

C2 - 34238441

AN - SCOPUS:85108648242

SN - 0735-1097

VL - 78

SP - 193

EP - 195

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 2

ER -